← All tickers

Is CCCC Worth Buying in 2026?

C4 Therapeutics, Inc.

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-08-16

Here’s whether C4 Therapeutics, Inc. (CCCC) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.

🔵
Neutral

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); strong 1-year return of +80.4%; 3-month momentum positive (+19.1%). Concerns: 50-day MA is falling (-0.25% over 10 days); RSI 74 — overbought, elevated pullback risk. Currently 18.0% off its 52-week high. Score: +3/7.

Ready to act on this? 📈 Trade on Webull

CCCC is in a confirmed uptrend, trading above both its 50-day ($3.90) and 200-day ($2.93) moving averages. With an RSI of 73.7, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +80.4% compares to +20.4% for SPY (beat the market by 60.1%).

$10,000 invested 1 year ago → $18,043 today
vs. S&P 500 (SPY) — same period beat market by 60.1%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($2.93)
✓Above 50-day MA ($3.90)
!RSI(14) neutral zone (30–70) — currently 73.7
✓Positive return (+80.4%)
!Within 10% of period high (−18.0%)
Period Range $4.24
$1.69 $5.17
RSI (14) 73.7
0 · OversoldOverbought · 100

Key Metrics

Price$4.24
Period Return+80.4%
Period High$5.17
Period Low$1.69
Drawdown−18.0%
MA-50$3.90
MA-200$2.93
RSI (14)73.7
Avg Volume (30d)2.9M
vs. SPYbeat by 60.1%
Return Rank#189 of 1252

Trade CCCC

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers